Compare PDS & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PDS | MRVI |
|---|---|---|
| Founded | 1951 | 2014 |
| Country | Canada | United States |
| Employees | N/A | 416 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 992.1M | 890.9M |
| IPO Year | 1998 | 2020 |
| Metric | PDS | MRVI |
|---|---|---|
| Price | $75.49 | $5.99 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $122.33 | $4.13 |
| AVG Volume (30 Days) | 78.5K | ★ 3.1M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $185,743,000.00 |
| Revenue This Year | $5.66 | $12.54 |
| Revenue Next Year | $2.31 | $7.87 |
| P/E Ratio | $884.15 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $48.59 | $1.99 |
| 52 Week High | $103.80 | $6.55 |
| Indicator | PDS | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 30.20 | 69.95 |
| Support Level | $55.33 | $3.27 |
| Resistance Level | $102.00 | N/A |
| Average True Range (ATR) | 2.75 | 0.32 |
| MACD | -1.15 | 0.05 |
| Stochastic Oscillator | 4.84 | 69.98 |
Precision Drilling Corp is a provider of contract drilling, completion, and production services to oil and natural gas exploration and production companies in Canada, the United States, and certain international locations. The company operates through two industry segments: Contract Drilling Services, which generates maximum revenue and includes drilling rigs, procurement and distribution of oilfield supplies, and the manufacture, sale, and repair of drilling equipment; and Completion and Production Services, which includes service rigs, oilfield equipment rental, and camp services. The company generates the majority of its revenue from the United States.
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.